Breaks Categories: Stock Spotlights

ThursdayJan 26, 2017 1:17 pm

NetworkNewsBreaks – Fuwei Films (NASDAQ: FFHL) Shares Surge on Potential of New Polyester Film Sales Contract

Shares of Fuwei Films (NASDAQ: FFHL) are up 54% this morning on news the company has signed an annual sales contract with Eternal Electronic Material (Guangzhou) Co., Ltd., an existing costumer that purchases polyester film for printed circuit boards (PCB). Fuwei expects that the new contract for 2017 will increase the total polyester film for PCB sales in the first quarter of the year by approximately 34.5% compared to the same period of 2016. "Our company will continue to execute a portfolio of products that optimizes a higher margin strategy. We intend to continue to leverage our R&D capabilities and…

Continue Reading

WednesdayJan 25, 2017 1:36 pm

NetworkNewsBreaks – Advantage Lithium (AVLIF) Tackles Growing Lithium Demand with Strongest Drill Results to Date

Advantage Lithium (OTCQB: AVLIF) is a lithium explorer and developer with an international portfolio of quality assets. The company wrapped up 2016 with results from its Clayton NE project, in which the company drilled lithium brines on all three of its drill holes in the Clayton Valley, Nevada. Lithium brines intercepted by the third drill hole demonstrated the strongest results to date, showing peak values of 322 mg/l lithium. According to the company, the demand for lithium is growing rapidly with predicted growth to triple over the next 10 years, and it already exceeds supply by 15%. The increasing battery…

Continue Reading

WednesdayJan 25, 2017 12:28 pm

NetworkNewsBreaks – GSI Technology, Inc. (NASDAQ: GSIT) Targets High-Performance Memory Market and In-Place Associative Compute Market

GSI Technology (NASDAQ: GSIT) historically designs, develops and markets high-performance memory products primarily for networking and telecommunication equipment manufacturers, in a market currently estimated at $500 million.  More recently, it has expanded its development strategy to include RadHard SRAM targeted at aerospace and defense applications and a patented in-place associative compute solution for applications such as machine learning, image detection, speech recognition, recommender systems for e-commerce, data mining, and cyber security, a booming market with huge growth potential over the next decade and beyond.  GSI is primed to capitalize on the many opportunities afforded to it by its patented in-place…

Continue Reading

WednesdayJan 25, 2017 12:23 pm

NetworkNewsBreaks – Akebia Therapeutics, Inc. (NASDAQ: AKBA) Remains Focused on Further Development of Vadadustat

Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company engaged in discovering and developing novel therapeutic solutions that leverage hypoxia inducible factor (HIF) biology, a primary regulator involved in multiple major biological pathways. According to an earlier Aegis report (http://nnw.fm/F4ezY), Akebia’s lead product candidate, vadadustat, has an impressive 60 percent probability of clinical success. Vadadustat is currently in phase III trials, after encouraging results were reported during phase II testing. In December 2016, Akebia signed a collaboration and license agreement with Otsuka Pharmaceutical (OTC: OTSKF) for vadadustat in the U.S. The companies will equally share the revenue and commercialization costs of…

Continue Reading

WednesdayJan 25, 2017 10:29 am

NetworkNewsBreaks – Breaking News: Dow Rockets above 20,000, Clinches Milestone under Trump Administration

No matter your view on President Trump, there’s no arguing his initial influence on the markets. The Dow Jones Industrial Average (DJIA) this morning jumped more than 100 points to cross the 20,000 mark for the first time in its 120-year history. The rally comes despite a flurry of controversy as the new Administration sets the pen to abortion, illegal voting, a border wall, and other social issues. While CNBC’s Jim Cramer recently discussed how President Trump’s plan to cut taxes would grow the economy, the Dow’s milestone could also reflect economic solidarity and recent jobs report attributed to former…

Continue Reading

WednesdayJan 25, 2017 10:02 am

NetworkNewsBreaks – Mobivity Holdings Corp. (MFON) Establishes Notable Growth in 2016, Starts New Year with New Deal

Mobivity Holdings (OTCQB: MFON) develops and operates proprietary platforms that help brands and enterprises conduct national and localized, data-driven mobile marketing campaigns. By revolutionizing the way companies use their data to predict and influence customer behavior to accelerate their business, Mobivity is a leader in the Cognitive Transaction Data Platform Category. The company was recently chosen by Dutch Bros Coffee to provide its SmartMessenger enterprise mobile marketing solution to help the coffee chain manage its 275+ locations. Mobivity Holdings in November reported revenues for the first nine months of 2016 at $6.1 million, an increase of $2.8 million, or 83%,…

Continue Reading

WednesdayJan 25, 2017 9:58 am

NetworkNewsBreaks – ClearSign Combustion Corporation (CLIR) Achieves Low Levels of NOx Emissions with Duplex Burner

Companies are making substantial efforts to lower their emissions with Selective Catalytic Reduction (SCR) and Low NOx Burners (LNB). Because these solutions create both financial and operational challenges, ClearSign Combustion Corporation (NASDAQ: CLIR) has introduced its Duplex™ Technology. Duplex burner technology is designed to improve operations by offering a more balanced fuel-air blend to nearly eliminate the formation of nitrogen oxide and increase thermal capacity, while reducing operational and maintenance costs. Duplex™ can be applied to refinery process heaters, steam generation, and virtually any other system in which there is a flame. The company recently announced the completion and customer…

Continue Reading

TuesdayJan 24, 2017 9:46 am

NetworkNewsBreaks – WidePoint Corporation (NYSE: WYY) Forecasts Strong 2017 Performance on Key Corporate Variables

WidePoint Corporation (NYSE: WYY) provides managed mobility services, telecommunications lifecycle management, and cybersecurity solutions. Since its first merger in 1998, WidePoint has demonstrated a pattern of growth through strategic mergers with highly specialized regional IT consulting companies, most of which have been in business for decades. In November 2016, WidePoint posted third-quarter net revenue of approximately $22.1 million, an increase of 30% compared to $17.0 million in the third quarter of 2015. The company also cut its net loss to $148,000 in the third quarter of 2016 compared to a loss of $1.8 million in the year ago quarter. WidePoint was also operationally…

Continue Reading

TuesdayJan 24, 2017 9:39 am

NetworkNewsBreaks – Finjan Holdings, Inc. (NASDAQ: FNJN) Keeps Pace as Best Cybersecurity Patent Litigator

Finjan Holdings (NASDAQ: FNJN) provides intellectual property licensing and enforcement services, develops mobile security applications, provides consulting services, and invests in innovation. Over the last year, the company has built a reputation as cybersecurity's top patent litigator. In August of 2015 Finjan received a unanimous jury verdict and $39.5M in damages against Blue Coat that its patents were valid and mostly infringed. More recently, in September of 2016, Finjan received a jury verdict in its trial against Sophos confirming the validity and infringement of its patents and $15M in damages. The company has several pending infringement lawsuits against Blue Coat, as…

Continue Reading

TuesdayJan 24, 2017 9:33 am

NetworkNewsBreaks – Delcath Systems, Inc. (NASDAQ: DCTH) Investigating Novel Therapy for the Treatment of Certain Unresectable Liver Cancers

With an initial potential market opportunity in ocular melanoma liver metastases of between $104 million and $260 million at stake, Delcath Systems (NASDAQ: DCTH) is working with the U.S. FDA toward approval of the company’s Melphalan/Hepatic Delivery System (Melphalan/HDS) chemotherapy system for treatment of certain unresectable liver cancers. The Melphalan/HDS system facilitates the delivery of melphalan directly to the liver and, consequently, allows the administration of higher doses. The blood is then filtered to reduce the level of melphalan and returned to the patient, thereby potentially reducing hematologic side effects. In 2016, Delcath initiated its global FOCUS phase 3 trial in hepatic dominant ocular…

Continue Reading